Lynparza is already the most widely-used PARP inhibitor, and the new results could help to extend its lead over rivals in the class like GSK's Zejula (niraparib), Pfizer's Talzenna (talazoparib ...
Pfizer (PFE) will end global development and commercialization of Beqvez, a gene therapy for hemophilia, Nikkei learned Thursday, after the ...
New Diagnostics, AI Breakthroughs, and Next-Gen Therapies Are Transforming the Oncology Market. The oncology sector is experiencing <stron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback